← FDA Drug Approvals (Drugs@FDA)
EMTRICITABINE; RILPIVIRINE; TENOFOVIR ALAFENAMIDE
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: CIPLA LIMITED · Approved 2022-09-27
Drug application
- FDA Application #
ANDA214058- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- EMTRICITABINE; RILPIVIRINE; TENOFOVIR ALAFENAMIDE
- Generic name
- Emtricitabine
- Active ingredients
- EMTRICITABINE; RILPIVIRINE; TENOFOVIR ALAFENAMIDE
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- None (Tentative Approval)
- Sponsor
- CIPLA LIMITED
- First approval
- 2022-09-27
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown